文献速递血液透析通路

商业经皮动静脉瘘创建系统的解剖适用性真实世界评估

Anatomic suitability for commercially available percutaneous arteriovenous fistula creation systems.
PubMed 文献 · J Vasc Surg · 2020-10-15

本研究对58例男性患者的116条上肢进行静脉测绘,依据各系统说明书评估Ellipsys(EL)和WavelinQ(WQ)经皮动静脉瘘(pAVF)系统的解剖适用性。按说明书WQ适用率93%显著高于EL的52%(P<.0001),但采用更近发表指南后两者临床可用性无显著差异(55% vs 44%,P=.09)。深部穿通肘静脉尺寸是主要限制因素。

要点

  • 按说明书WQ解剖适用率93%显著高于EL的52%。
  • 采用更近指南后两者临床可用性无显著差异(55% vs 44%)。
  • 深部穿通肘静脉尺寸是限制pAVF系统使用的主要因素。

核心结论

  • 仅按说明书评估时WQ解剖适用性高于EL,但综合pAVF创建全部要求后两者可用性无显著差异。
  • 解剖分析表明pAVF创建可占血液透析通路实践的相当部分。

研究设计与样本

  • 单中心回顾性队列研究,纳入58例男性患者共116条上肢。
  • 所有患者接受双侧上肢广泛静脉测绘,依据制造商说明书评估解剖适用性,并参照已发表解剖指南确定临床可用性。
  • 同时评估桡头动静脉瘘(RCF)创建适用性,并构建临床算法模拟实际使用频率。

主要发现

  • 按说明书,WQ系统上肢适用率为93%,EL系统为52%(P < .0001)。
  • 同一人群中32%的上肢解剖适合创建RCF。
  • 采用更近发表指南,WQ系统总体临床可用性为55%,EL系统为44%(P = .09)。
  • 两种pAVF系统的可用性均主要受限于深部穿通肘静脉尺寸。
  • EL可用性还受限于肘前穿通静脉与近端桡动脉的邻近程度。

关键数值与推荐

  • 根据临床算法,31%的队列初始通路为RCF,32%为WQ,23%为EL,18%为肘部手术瘘,17%为移植物。

临床怎么用

  • 在血管通路规划中应依据说明书和更近指南综合评估pAVF解剖适用性。
  • 深部穿通肘静脉尺寸是选择pAVF系统时需重点评估的解剖参数。
  • 临床算法提示pAVF可作为血液透析通路实践的重要组成部分,但需结合RCF优先策略。

局限性

  • 研究仅纳入男性退伍军人患者,结果外推需谨慎。
  • 样本量较小(58例患者,116条上肢),可能影响统计效能。
  • 临床算法基于假设偏好,实际临床决策可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Food and Drug Administration recently approved two percutaneous arteriovenous fistula creation systems: the Ellipsys vascular access (EL) system and WavelinQ EndoAVF (WQ) system. Although the initial clinical trials of each system have demonstrated a high success rate, little detail on anatomic suitability was provided. We sought to determine the real-world applicability of the EL and WQ systems by studying them in a single representative cohort. METHODS: All patients receiving a first-time arteriovenous access consultation at a single Veterans Affairs institution underwent extensive vein mapping of the bilateral upper extremities. Anatomic suitability was assessed in accordance with the manufacturer's instructions for use (IFU), and clinical usability was determined using additional published anatomic guidelines. The suitability for radiocephalic fistula (RCF) creation was also assessed. To estimate how often these systems would be used in practice, a clinical algorithm was created, with a preference for RCF creation, followed by percutaneous arteriovenous fistula (pAVF) creation, surgical fistula creation at the elbow, and, finally, graft placement. RESULTS: During the study period, 116 upper extremities were measured in 58 male patients. Per the IFU, the rate of extremity suitability was 93% and 52% for the WQ and EL systems, respectively (P < .0001). In the same population, 32% of the extremities had acceptable anatomy for RCF creation. The overall clinical usability of these systems using more recent published guidelines was 55% for the WQ system and 44% for the EL system (P = .09). The usability of both pAVF systems was most limited by the size of the deep perforating cubital vein. The proximity of the antecubital perforator vein and proximal radial artery additionally limited EL usability. Based on the clinical algorithm, initial access creation would have been RCF creation for 31% of the cohort, followed by the WQ (32%), the EL (23%), surgical fistula creation at the elbow (18%), and graft placement (17%). CONCLUSIONS: Anatomic suitability was greater for WQ than for EL when considering only the IFU. Once the full requirements for pAVF creation were considered, we found no significant differences in usability between the two systems. Anatomic analysis showed that pAVF creation can constitute a substantial part of a hemodialysis access practice.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Popli K, Dittman JM, Amendola MF, et al. Anatomic suitability for commercially available percutaneous arteriovenous fistula creation systems. J Vasc Surg. 2020. PMID: 33068764. doi:10.1016/j.jvs.2020.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。